View in EDS HTML Full Text PDF Full Text

Post-marketing safety surveillance of Amivantamab: a real world study based on the FDA adverse event reporting system.

Saved in:
Bibliographic Details
Title: Post-marketing safety surveillance of Amivantamab: a real world study based on the FDA adverse event reporting system.
Authors: Fu X; Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.; Clinical Pharmacy Center, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.; National Medical Products Administration Key Laboratory for Research and Evaluation of Drug Metabolism & Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, Guangdong, China., Zeng D; Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.; Cancer Center, the Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Foshan, Guangdong, China.; Foshan Key Laboratory of Translational Medicine in Oncology, the Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Foshan, Guangdong, China., Li M; Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China., Wu J; Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China., Yang Y; Clinical Pharmacy Center, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.; National Medical Products Administration Key Laboratory for Research and Evaluation of Drug Metabolism & Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, Guangdong, China., Mao Q; Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China., Qiu W; Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China., Huang X; Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China., Fang Y; Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China., Jiang L; Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China., Hu P; Department of Obstetrics and Gynecology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China., Wu J; Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China., Liao W; Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.; Cancer Center, the Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Foshan, Guangdong, China.; Foshan Key Laboratory of Translational Medicine in Oncology, the Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Foshan, Guangdong, China.
Source: Expert opinion on drug safety [Expert Opin Drug Saf] 2026 Jul; Vol. 25 (7), pp. 1309-1317. Date of Electronic Publication: 2025 Feb 26.
Publication Type: Journal Article
Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101163027 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-764X (Electronic) Linking ISSN: 14740338 NLM ISO Abbreviation: Expert Opin Drug Saf Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40001304
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Post-marketing safety surveillance of Amivantamab: a real world study based on the FDA adverse event reporting system.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Fu+X%22">Fu X</searchLink>; Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.; Clinical Pharmacy Center, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.; National Medical Products Administration Key Laboratory for Research and Evaluation of Drug Metabolism & Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, Guangdong, China.<br /><searchLink fieldCode="AU" term="%22Zeng+D%22">Zeng D</searchLink>; Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.; Cancer Center, the Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Foshan, Guangdong, China.; Foshan Key Laboratory of Translational Medicine in Oncology, the Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Foshan, Guangdong, China.<br /><searchLink fieldCode="AU" term="%22Li+M%22">Li M</searchLink>; Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.<br /><searchLink fieldCode="AU" term="%22Wu+J%22">Wu J</searchLink>; Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.<br /><searchLink fieldCode="AU" term="%22Yang+Y%22">Yang Y</searchLink>; Clinical Pharmacy Center, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.; National Medical Products Administration Key Laboratory for Research and Evaluation of Drug Metabolism & Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, Guangdong, China.<br /><searchLink fieldCode="AU" term="%22Mao+Q%22">Mao Q</searchLink>; Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.<br /><searchLink fieldCode="AU" term="%22Qiu+W%22">Qiu W</searchLink>; Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.<br /><searchLink fieldCode="AU" term="%22Huang+X%22">Huang X</searchLink>; Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.<br /><searchLink fieldCode="AU" term="%22Fang+Y%22">Fang Y</searchLink>; Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.<br /><searchLink fieldCode="AU" term="%22Jiang+L%22">Jiang L</searchLink>; Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.<br /><searchLink fieldCode="AU" term="%22Hu+P%22">Hu P</searchLink>; Department of Obstetrics and Gynecology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Wu+J%22">Wu J</searchLink>; Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.<br /><searchLink fieldCode="AU" term="%22Liao+W%22">Liao W</searchLink>; Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.; Cancer Center, the Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Foshan, Guangdong, China.; Foshan Key Laboratory of Translational Medicine in Oncology, the Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Foshan, Guangdong, China.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101163027%22">Expert opinion on drug safety</searchLink> [Expert Opin Drug Saf] 2026 Jul; Vol. 25 (7), pp. 1309-1317. <i>Date of Electronic Publication: </i>2025 Feb 26.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Taylor+%26+Francis%22">Taylor & Francis </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101163027 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1744-764X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214740338%22">14740338 </searchLink><i>NLM ISO Abbreviation: </i>Expert Opin Drug Saf <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40001304
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1080/14740338.2025.2471512
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1309
    Titles:
      – TitleFull: Post-marketing safety surveillance of Amivantamab: a real world study based on the FDA adverse event reporting system.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Fu X
      – PersonEntity:
          Name:
            NameFull: Zeng D
      – PersonEntity:
          Name:
            NameFull: Li M
      – PersonEntity:
          Name:
            NameFull: Wu J
      – PersonEntity:
          Name:
            NameFull: Yang Y
      – PersonEntity:
          Name:
            NameFull: Mao Q
      – PersonEntity:
          Name:
            NameFull: Qiu W
      – PersonEntity:
          Name:
            NameFull: Huang X
      – PersonEntity:
          Name:
            NameFull: Fang Y
      – PersonEntity:
          Name:
            NameFull: Jiang L
      – PersonEntity:
          Name:
            NameFull: Hu P
      – PersonEntity:
          Name:
            NameFull: Wu J
      – PersonEntity:
          Name:
            NameFull: Liao W
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 07
              Text: 2026 Jul
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1744-764X
          Numbering:
            – Type: volume
              Value: 25
            – Type: issue
              Value: 7
          Titles:
            – TitleFull: Expert opinion on drug safety
              Type: main
ResultId 1